Opinion|Videos|November 8, 2024
Criteria for Transitioning Patients from Bispecific Therapy to Community Oncologist Care in Multiple Myeloma
Panelists discuss how determining a patient's readiness to transition back to community oncology care after bispecific therapy involves assessing multiple factors including treatment response, toxicity resolution, overall stability, and the community practice's capabilities.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What criteria or thresholds do you use to determine when a patient is ready for transition back to the community oncologist after bispecific therapy? (e.g. time since treatment, resolution of toxicities, evidence of response)
- How do social factors play into the referral process?
- How do the AEs differ based on the class of bispecific? Which AEs are you seeing in practice?
- How are they managed?
Advertisement
Related to this article
“If it is successful, you should be able to access this combination wherever you are,” said Natalie S. Callander, MD, of the UW Carbone Cancer Center.
Data from the phase 3 CERVINO trial support the application for etentamig as a treatment for adults with relapsed or refractory multiple myeloma.
The MagnetisMM-32 trial may support elranatamab as an important option for those whose disease has progressed following anti-CD38 therapy and lenalidomide.
In the phase 1/2 Bela-DRd study, over 90% of patients responded to belantamab mafodotin plus daratumumab, lenalidomide, and dexamethasone.
Advertisement
Advertisement
Trending on CancerNetwork
1
Blood mRNA Model Predicts Castration Resistance in Metastatic Prostate Cancer
2
CD19 CAR T Cell Therapy for Treatment-Refractory Seropositive Rheumatoid Arthritis: A Phase 1 Trial
3
Predicting Severe Immune-Related Toxicities in Lung Cancer Immunotherapy
4
Outpatient Treatment-Related Toxicity After Hospital Discharge Among Patients Receiving Lifileucel for Advanced Melanoma
5